Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type

Pediatric Transplantation

Volumn 16, Issue 5, 2012, Pages

  Chaudhuri, Abanti ^a   Kambham, Neeraja ^a   Sutherland, Scott ^a   Grimm, Paul ^a   Alexander, Steven ^a   Concepcion, Waldo ^a   Sarwal, Minnie ^a   Wong, Cynthia ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

pediatric transplantation; recurrence of nephrotic syndrome; rituximab

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FUROSEMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ANAMNESIS; ARTICLE; CASE REPORT; CHILD; CONGENITAL NEPHROTIC SYNDROME; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; GENE; GENE MUTATION; HUMAN; KIDNEY TRANSPLANTATION; NPHS 1 GENE; PERITONEAL DIALYSIS; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; NEPHROTIC SYNDROME; RECURRENCE;

EID: 84863716525     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01519.x     Document Type: Article

References (28)

1. Patrakka J, Kestilä M, Wartiovaara J, et al., Congenital nephrotic syndrome (NPHS1): Features resulting from different mutations in Finnish patients. Kidney Int 2000: 58: 972-980.
2. Salomon R, Gubler MC, Niaudet P,. Genetics of the nephrotic syndrome. Curr Opin Pediatr 2000: 12: 129-134.
3. Niaudet P,. Congenital nephrotic syndrome: Commentary. Pediatr Nephrol 2001: 16: 190-191.
4. Patrakka J, Ruotsalainen V, Reponen P, et al., Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: Role of nephrin. Transplantation 2002: 73: 394-403.
5. Holmberg C, Antikainen M, Ronnholm K, Ala Houhala M, Jalanko H,. Management of congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol 1995: 9: 87-93.
6. Kuusniemi AM, Qvist E, Sun Y, et al., Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1). Transplantation 2007: 83: 1316-1323.
7. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM,. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008: 8: 2607-2617.
8. Racusen LC, Solez K, Colvin RB, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713-723.
9. Schwartz GJ, Gauthier B,. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985: 106: 522-526.
10. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M,. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991: 40: 453-460.
11. Esnault VL, Besnier D, Testa A, et al., Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol 1999: 10: 2014-2017.
12. Dantal J, Godfrin Y, Koll R, et al., Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 1998: 9: 1709-1715.
13. Kakumitsu H, Higuchi M, Tanaka K, Shibuya T,. Nephrotic syndrome in a patient with intravascular lymphomatosis. Intern Med 2003: 42: 98-101.
14. Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE,. Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 2003: 60: 242-247.
15. Smith GC,. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 2007: 22: 893-898.
16. Benz K, Dotsch J, Rascher W, Stachel D,. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004: 19: 794-797.
17. Gilbert RD, Hulse E, Rigden S,. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006: 21: 1698-1700.
18. Nakayama M, Kamei K, Nozu K, et al., Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008: 23: 481-485.
19. Suri M, Tran K, Sharma AP, Filler G, Grimmer J,. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 2008: 40: 807-810.
20. Hristea D, Hadaya K, Marangon N, et al., Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007: 20: 102-105.
21. Prytula A, Iijima K, Kamei K, et al., Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010: 25: 461-468.
22. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M,. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005: 20: 1660-1663.
23. Pescovitz MD, Book BK, Sidner RA,. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006: 354: 1961-1963.
24. Marks SD, Mcgraw M,. Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 2007: 22: 158-160.
25. Yabu JM, Ho B, Scandling JD, Vincenti F,. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008: 8: 222-227.
26. Kamei K, Ito S, Nozu K, et al., Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009: 24: 1321-1328.
27. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K,. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008: 93: 401-406.
28. Terrier B, Amoura Z, Ravaud P, et al., Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010: 62: 2458-2466.